Stockreport

Legend Biotech CARVYKTI Milestones Contrast With Mixed Long Term Share Returns [Yahoo! Finance]

Legend Biotech Corporation - American Depositary Shares  (LEGN) 
PDF Legend Biotech reported that more than 10,000 patients have now been treated with its CARVYKTI multiple myeloma therapy. The company announced an expansion of its Rar [Read more]